Severe Asthma: Eight-Market Drug Forecast and Market Analysis

Severe Asthma: Eight-Market Drug Forecast and Market Analysis

Summary

This new publication covers the severe asthma market over the forecast period of 2023-33.

GlobalData estimated the total severe asthma market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 16.2% of the global severe asthma market in 2023 with an estimated value of $825.1 million. Japan’s severe asthma market was estimated to be $30.6 million in 2023, accounting for 0.6% of the market. China’s severe asthma market was estimated to be $58.4 million in 2023, accounting for 1.1% of the market.

Major drivers of growth in the PsO market over the forecast period include -

• Increased adoption of biologics: The expansion of biologic therapies, including [Dupixent (dupilumab), Fasenra (benralizumab), Tezspire (tezepelumab)], will contribute to market growth despite their high costs. These therapies provide targeted treatment for Type 2 inflammation-driven asthma and are increasingly prescribed due to their effectiveness in reducing exacerbations.
• Expansion of market access and reimbursement policies: Improved insurance coverage and reimbursement policies for biologics in key markets, particularly in the US and 5EU, will facilitate wider adoption and drive revenue growth.
• Rising prevalence and increased diagnosis rates: The number of diagnosed severe asthma patients is expected to grow as awareness improves and healthcare systems implement better screening and management strategies.
• Introduction of novel therapies: The pipeline for severe asthma includes next-generation biologics with more convenient dosing schedules targeting novel inflammatory pathways (such as depemokimab, lunsekimig, AZD-8630) which may further drive market expansion.

The major barriers of growth in the PsO market during the forecast period include -

• High cost of biologics and access limitations: The high price of biologics continues to be a significant barrier, particularly in regions with stringent reimbursement policies. Cost-effectiveness assessments and payer constraints may limit broader adoption.
• Limited treatment options for non-Type 2 asthma: While targeted biologics have transformed the treatment landscape for Type 2 severe asthma, effective options for non-Type 2 (neutrophilic or mixed-inflammatory) asthma remain limited, presenting an ongoing unmet need.
• Patent expirations and biosimilar competition: Several leading biologics are expected to face patent expirations during the forecast period, potentially leading to increased competition from biosimilars and downward pressure on pricing.
• Patient adherence challenges: Some patients with severe asthma may struggle with adherence to biologic therapies due to factors such as administration method, dosing frequency, or accessibility, impacting long-term treatment outcomes.

Key Highlights

• In 2023, GlobalData estimated that the global severe asthma market reached $5.1 billion across the 8MM, and expects the severe asthma market to grow at a strong Compound Annual Growth Rate of 7.1%, reaching sales of $10.1 billion by 2033.

Major drivers of the severe market growth over the forecast period are the:

• The expansion of biologic therapies, including Dupixent (dupilumab), Fasenra (benralizumab), and Tezspire (tezepelumab).
• Rising prevalence and increased diagnosis rates of severe asthma.
• Introduction of novel severe asthma therapies.

Scope

• Overview of Severe Asthma, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized severe asthma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the severe asthma therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for severe asthma treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global severe asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM severe asthma therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM severe asthma therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note: this is delivered as a zip file.